Search

Your search keyword '"Biasco G"' showing total 907 results
Start Over Author "Biasco G"
907 results on '"Biasco G"'

1. An online international comparison of palliative care identification in primary care using the Surprise Question

Author

White, N., Oostendorp, L.J., Vickerstaff, V., Gerlach, C., Engels, Y., Maessen, M., Tomlinson, C., Wens, J., Leysen, B., Biasco, G., Zambrano, S., Eychmüller, S., Avgerinou, C., Chattat, R., Ottoboni, G., Veldhoven, C., Stone, P., White, N., Oostendorp, L.J., Vickerstaff, V., Gerlach, C., Engels, Y., Maessen, M., Tomlinson, C., Wens, J., Leysen, B., Biasco, G., Zambrano, S., Eychmüller, S., Avgerinou, C., Chattat, R., Ottoboni, G., Veldhoven, C., and Stone, P.

Abstract

Item does not contain fulltext, BACKGROUND: The Surprise Question ('Would I be surprised if this patient died within 12 months?') identifies patients in the last year of life. It is unclear if 'surprised' means the same for each clinician, and whether their responses are internally consistent. AIM: To determine the consistency with which the Surprise Question is used. DESIGN: A cross-sectional online study of participants located in Belgium, Germany, Italy, The Netherlands, Switzerland and UK. Participants completed 20 hypothetical patient summaries ('vignettes'). Primary outcome measure: continuous estimate of probability of death within 12 months (0% [certain survival]-100% [certain death]). A threshold (probability estimate above which Surprise Question responses were consistently 'no') and an inconsistency range (range of probability estimates where respondents vacillated between responses) were calculated. Univariable and multivariable linear regression explored differences in consistency. Trial registration: NCT03697213. SETTING/PARTICIPANTS: Registered General Practitioners (GPs). Of the 307 GPs who started the study, 250 completed 15 or more vignettes. RESULTS: Participants had a consistency threshold of 49.8% (SD 22.7) and inconsistency range of 17% (SD 22.4). Italy had a significantly higher threshold than other countries (p = 0.002). There was also a difference in threshold levels depending on age of clinician, for every yearly increase, participants had a higher threshold. There was no difference in inconsistency between countries (p = 0.53). CONCLUSIONS: There is variation between clinicians regarding the use of the Surprise Question. Over half of GPs were not internally consistent in their responses to the Surprise Question. Future research with standardised terms and real patients is warranted.

Published
2022

21. Epidemiology

Author

Fixa, B., Komárková, O., Krejsek, K., Bures, J., Nozicka, Z., Giorcelli, W., Rodi, M., Camisasca, G., Martinotti, R. G., Mendall, M. A., Goggin, P. M., Molineaux, Nicola, Levy, Joanne, Toosy, T., Strachan, D., Northfield, T. C., Vorobjova, T., Vassiljev, V., Kisand, K., Wadström, T., Uibo, R., Zotz, R. B., Xu, S. G., Recklinghausen, G. von, Meusers, P., Goebell, H., Rhee, K. H, Youn, H. S., Paik, S. K., Lee, W. K., Cho, M. J., Park, C. K., Li, Yuyuan, Hu, Pinjin, Du, Guoguang, Wong, Zhijin, Hazell, Stuart L., Mitchell, Hazel M., Korwin, J. D. de, Remot, P., Hartemann, Ph, Catelle, A., Conroy, M. C., Schmitt, J., Stolte, M., Wellens, E., Bethke, B., Ritter, M., Eidt, H., Zanten, S. Veldhuyzen van, Best, L., Bezanson, G., Marrie, T., Poniewierka, E., Gosciniak, G., Matysiak-Budnik, T., Quatrini, M., Boni, F., Baldassarri, A. R., Vecchi, A. De, Castelnovo, C., Viganò, E., Tenconi, L., Bianchi, P. A., Carlucci, A., Ferrini, G., Bianco, I, Larcinese, G., Sciascio, A. Di, Fly, G. F., Hauge, T., Persson, J., Coelho, L. G. V., Teixeira, M. M., Passos, M. C. F., Givisiez, C. B., Santos, C. M. F. R., Rodrigues, C. J. S., Chausson, Y., Castro, L. P., Hyvärinen, Hannu, Seppälä, Kari, Kivilaakso, Eero, Kosunen, Timo, Gormse, Martin, Pilotto, A., Vianello, F., Tornaboni, D., Dotto, P., Battaglia, G., Binda, F., Mario, F. Di, Donisi, P. M., Pasini, M., Benve-nuti, M. E., Stracca-Pansa, V., Pasquino, M., Jablonowski, H., Szelényi, H., Hengels, K. J., Strohmeyer, G., Banatvala, N., Mayo, K., Megraud, F., Jennings, R., Deeks, J. J., Feldman, R. A., Bulighin, G., Ederie, A., Pilati, S., Franzin, G., Zamboni, G., Maran, M., Musola, R., Tobin, A., Hackman, R. C., McDonald, G. B., Fatela, N., Cristino, J. Melo, Monteiro, L., Ramalho, F., Saragoça, A., Salgado, M. J., Moura, M. Cameiro de, Pretolani, S., Gasbarrini, G., Bonvicini, F., Baraldini, M., Tonelli, E., Gatto, M. R. A., Ghironzi, G. C., égraud, F. M, Bouchard, S., Lubcvzumiska-Kowalska, W., Knapik, Z., Meenan, J., Goggins, M., Shahi, C., Keeling, P. W. N., Keane, C., Weir, D. G., Vaira, D., Miglioli, M., Mulè, P., Holten, J., Menegati, M., Biasco, G., Vergura, M., Nannetti, A., Barbara, L., Boschini, A., Begnini, M., Menegatti, M., Ghira, C., D’Errico, A., Evans, D. G., Asnicar, M. A., Evans, D. J., Graham, D. Y., Lee, C. H., Coschieri, M., Fosse, T., Paul, M. C. St., Michiels, J. R., Delmont, J. P., Péroux, J. L., Pradier, C., Rampai, P., Pazzi, P., Merighi, A., Gamberini, S., Scarliarini, R., Bicochi, R., Libanore, M., Bisi, G., and Gulllini, S.

Published
1992
Full Text
View/download PDF

26. PS1020 SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS

Author

Cerchione, C., primary, Guadagnuolo, V., additional, Papayannidis, C., additional, Fontana, M.C., additional, Padella, A., additional, Iacobucci, I., additional, Simonetti, G., additional, Marconi, G., additional, Paolini, S., additional, Abbenante, M., additional, Parisi, S., additional, Volpato, F., additional, Ottaviani, E., additional, Delledonne, M., additional, Biasco, G., additional, and Martinelli, G., additional

Published
2019
Full Text
View/download PDF

32. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma

Author

Urbini, M, Astolfi, A, Pantaleo, Ma, Serravalle, S, DEI TOS, Angelo, Picci, P, Indio, V, Sbaraglia, M, Benini, S, Righi, A, Gambarotti, M, Gronchi, A, Colombo, Claudia, Dagrada, Gp, Pilotti, S, Maestro, R, Polano, M, Saponara, M, Tarantino, G, Pession, A, Biasco, G, Casali, Pg, Stacchiotti, S., Urbini, Milena, Astolfi, Annalisa, Pantaleo, MARIA ABBONDANZA, Serravalle, Salvatore, Dei Tos, Angelo Paolo, Picci, Piero, Indio, Valentina, Sbaraglia, Marta, Benini, Stefania, Righi, Alberto, Gambarotti, Marco, Gronchi, Alessandro, Colombo, Chiara, Dagrada, Gian Paolo, Pilotti, Silvana, Maestro, Roberta, Polano, Maurizio, Saponara, Maristella, Tarantino, Giuseppe, Pession, Andrea, Biasco, Guido, Casali, Paolo Giovanni, and Stacchiotti, Silvia

Subjects
Receptors, Steroid, Cancer Research, Oncogene Proteins, Fusion, DNA-Binding Protein, Chondrosarcoma, Groin, Fluorescence, NO, Genetic, DNA-Binding Proteins, Female, HSC70 Heat-Shock Proteins, Humans, In Situ Hybridization, Middle Aged, Neoplasms, Connective and Soft Tissue, Oncogene Proteins, Fusion, Receptors, Steroid, Thyroid Hormone, Tomography, X-Ray Computed, Genetics, In Situ Hybridization, Fluorescence, Receptors, Thyroid Hormone, HSC70 Heat-Shock Protein, Tomography, X-Ray Computed, Neoplasms, Connective and Soft Tissue, Human
Abstract

Extraskeletal myxoid chondrosarcoma (EMC) is a very rare sarcoma most often arising in the soft tissue. Rare EMC of the bone have been reported. EMC exhibits distinctive clinico-pathological and genetic features; however, despite the name, it lacks any feature of cartilaginous differentiation. EMC is characterized by the rearrangement of the NR4A3, which, in most cases (about 62-75%), is fused with EWSR1 and less frequently with other partners, including TAF15 (27%), TCF12 (4%), TFG, and FUS. We herein report the identification by whole-transcriptome sequencing of HSPA8 as a novel fusion partner of NR4A3 in a case of EMC. FISH analysis confirmed the presence of a genomic HSPA8-NR4A3 translocation in the vast majority of tumor cells. Our findings expand the spectrum of NR4A3 fusion partners involved in EMC pathobiology.

Published
2017

38. Foreword

Author

Biasco, G and Amadori, D

Published
1994

41. Cross-cultural differences in hospices. A retrospective study in Italy

Author

Brighi N., Colazzo A. L., Bolognesi D., Surbone A., Biasco G., Brighi N., Colazzo A.L., Bolognesi D., Surbone A., and Biasco G.

Subjects
Communication, Palliative care, Cultural competence, Hospice, End-of-life
Abstract

Aim: Increasing immigration in Italy poses challenges in providing cross-cultural palliative care (PC) and end-of-life (EOL) care. In this retrospective study we report the difficulties encountered by hospice operators caring for immigrant patients admitted to 16 hospices in Emilia Romagna from 2001 to 2011. Materials and methods: 327 immigrants were admitted in the study period (1.6% of total admissions). 379 hospice operators were surveyed regarding their experiences in cross-cultural encounters through a questionnaire. Answers were evaluated by the Mann-Whitney U test and chi-square test. 252 operators responded to the questionnaire (67% of total). Results: Relational aspects were the most frequent difficulties experienced by nurses during patient admission and hospitalization and by physicians during EOL. Language difficulties were reported by 75% of responders, regardless of their profession. Difficulties directly correlated with years of experience in a hospice (p=0.002). Conclusions: The results of this study suggest that hospice operators should learn how to deliver quality cross-cultural care. The problems encountered by both Italian doctors and nurses were most likely due to lack of teaching and training in cross-cultural communication and cultural competence. Immigrant patients admitted to Italian hospices are still few, but their number is expected to increase. Appropriate cross-cultural education should become mandatory for medical and nursing students as well as oncology and PC operators.

Published
2014

47. Metronomic capecitabine in advanced hepatocellualr cacinoma patients who have failed sorafenib: a phase II study

Author

De Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, Brandi G, and De Rosa F, Di Girolamo S, Corbelli J, Longobardi C, Agostini V, Andreone P, Serra C, Piscaglia F, Trevisani F, Golfieri R, Bolondi L, Pinna AD, Biasco G, Brandi G

Subjects
Metronomic chemotherapy, sorafenib, advanced hepatocellular carcinoma, antiangiogenic activity
Published
2011

49. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

Author

Bajetta, E, Di Bartolomeo, M, Mariani, L, Cassata, A, Artale, S, Frustaci, S, Pinotti, G, Bonetti, A, Carreca, I, Biasco, G, Bonaglia, L, Marini, G, Iannelli, A, Cortinovis, D, Ferrario, E, Beretta, E, Lambiase, A, Buzzoni, R, Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R, Bajetta, E, Di Bartolomeo, M, Mariani, L, Cassata, A, Artale, S, Frustaci, S, Pinotti, G, Bonetti, A, Carreca, I, Biasco, G, Bonaglia, L, Marini, G, Iannelli, A, Cortinovis, D, Ferrario, E, Beretta, E, Lambiase, A, Buzzoni, R, Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, and Buzzoni R

Abstract

BACKGROUND. The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS. A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2-15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS. Efficacy was evaluable in 134 patients (68 in Arm A, 66 in Arm B). Objective responses were observed in 46% of the patients (8% complete response [CR]), including 47% in Arm A (9% CR; 38% partial response [PR]) and 44% in Arm B (8% CR; 36% PR). The median progression-free survival was 8.3 months in Arm A and 7.6 months in Arm B. Among the first 52 patients treated with the higher doses, the most frequent Grade 3-4 adverse event was diarrhea (27%). The lower doses adopted in the subsequent 88 patients led to better diarrhea control, particularly in Arm A, and significant reductions in the incidence of all-grade hand-foot syndrome and abdominal pain. CONCLUSIONS. The capecitabine and irinotecan combination was a highly active first-line therapy in metastatic CRC. An acceptable safety profile was observed after dose reduction, particularly when irinotecan was administered on 1 day.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results